What Dual Wave Actually Does, And Why It Matters For RF Microneedling
Introduction
Most UK aesthetic practitioners have used, demoed, or at least watched a video of an RF microneedling device. The category has been in clinical use for over a decade. The treatment principle is well understood. Microneedles deliver radiofrequency energy into the dermis at a controlled depth, which produces a thermal injury that drives collagen and elastin remodelling.
What is less well understood, even by experienced injectors, is that not all RF microneedling devices deliver energy in the same way. The difference between a continuous wave device and a dual wave device is not a marketing distinction. It changes which clinical conditions the device can treat safely, which Fitzpatrick skin types can be treated without elevated risk, and which patients walk out of the clinic with a result they can see.
This article explains what dual wave RF microneedling actually does, how it differs from the continuous wave delivery used by most devices in the category, and why the clinical implications matter for any practitioner working with patients who present with vascular, pigmentary, or inflammatory conditions alongside the more common laxity and texture concerns.
What continuous wave RF microneedling does
Continuous wave RF microneedling is the original delivery method and remains the most common in the UK market. The needles insert to a set depth, then the device delivers RF energy in an uninterrupted stream for a defined duration, typically between one and four seconds per pass.
The continuous energy heats the dermis to a target temperature, somewhere between 60 and 70 degrees Celsius depending on the device and the protocol. That thermal injury triggers the wound healing response. Collagen contracts and remodels, elastin production increases, and over a course of three to four sessions the patient sees improved firmness, reduced fine lines, and refined texture.
This works. It works well for skin laxity, mild to moderate wrinkles, and texture concerns on Fitzpatrick I to III skin. Continuous wave RF microneedling is the workhorse of the category and the right tool for the job in most laxity focused treatments.
The limitation is everything outside that lane.
Continuous wave delivery generates significant heat in the surrounding tissue, including the epidermis. On Fitzpatrick IV to VI skin, melanocytes in the epidermis are more responsive to thermal injury, which raises the risk of post inflammatory hyperpigmentation. Most continuous wave devices either contraindicate higher Fitzpatrick types in their UK regulatory approval, or include strict cautions and reduced energy settings that limit clinical effect.
Continuous wave delivery is also poorly suited to vascular and pigmentary conditions. Melasma is famously made worse by uncontrolled thermal injury. Rosacea and post inflammatory erythema involve underlying vascular instability that responds badly to general dermal heating. Most continuous wave devices either avoid these indications entirely or treat them with limited success.
This is where dual wave changes the picture.
What Pulsed Wave delivers that Continuous Wave cannot
Sylfirm X is the only RF microneedling device on the UK market with a Pulsed Wave mode in addition to Continuous Wave. Pulsed Wave is not a marketing variation of continuous delivery. It is a fundamentally different way of delivering RF energy to the tissue.
In Pulsed Wave mode, the device delivers RF energy in short, controlled bursts rather than a continuous stream. The bursts are calibrated to target tissues that have higher water content and lower impedance, which includes abnormal blood vessels and inflammatory tissue, while passing through healthy surrounding tissue with minimal thermal effect.
The clinical implication is significant. Pulsed Wave mode can selectively target the underlying vascular and inflammatory components of melasma, rosacea, and post inflammatory erythema without producing the broad dermal heating that continuous wave delivery requires. The melanocytes in the epidermis are not stimulated, the surrounding healthy tissue is not heated to remodelling temperatures, and the underlying cause of the condition is addressed with far less collateral effect.
This is why Pulsed Wave mode is safe across all Fitzpatrick skin types, including IV, V, and VI, where continuous wave devices are typically contraindicated or restricted.
Why this matters for clinical practice
The practical effect of having both modes available on a single device is that a clinic can treat a far wider range of patients with a single piece of equipment.
A patient presenting with skin laxity and fine lines on Fitzpatrick II skin is treated with Continuous Wave mode at a depth of 1.5mm to 2.5mm, three sessions, typical RF microneedling outcome.
A patient presenting with melasma on Fitzpatrick IV skin, who would be turned away or referred out by most continuous wave devices, is treated with Pulsed Wave mode at a controlled depth, addressing the underlying vascular component of the condition without thermal stimulation of the melanocytes.
A patient presenting with rosacea and persistent facial redness, who has typically been managed with topical brimonidine and IPL with mixed results, is treated with Pulsed Wave mode targeting the abnormal vasculature directly.
A patient with acne scarring on Fitzpatrick V skin, who would be a high risk candidate for traditional fractional resurfacing, is treated with a combination of Pulsed Wave mode for the post inflammatory erythema and Continuous Wave mode at depth for the textural component of the scar.
This is not theoretical. These are the patient profiles being treated daily in clinics running Sylfirm X across the UK, including the practices of Mr Ayad Harb, Dr Preema Vig, Dr George Nema, and Dr Rita Rakus, who collectively cover some of the most diverse patient populations in London aesthetic medicine.
The depth control and impedance picture
Two further technical points worth covering, because they matter for clinical outcomes and they are not always discussed.
Depth control on Sylfirm X is set in 0.1mm increments from 0.3mm to 4.0mm. The minimum depth of 0.3mm is significant. Most RF microneedling devices have a minimum effective depth of 0.5mm or 1.0mm, which is too deep for periorbital and perioral work where the dermis is thin and the risk of unwanted thermal effect on adjacent structures is higher. The 0.3mm minimum opens up the eye area, the upper lip, and other technically demanding zones for treatment that some devices cannot enter safely.
Impedance monitoring is the other technical point. Sylfirm X measures the electrical impedance of the tissue at each insertion and adjusts the energy delivery to maintain a consistent thermal effect across the treatment area. Skin is not uniform, hydration varies, dermal thickness varies, vascular density varies. A device that delivers a fixed RF dose across an uneven tissue produces uneven results. A device that adjusts in real time based on tissue impedance produces a consistent thermal effect at every insertion point, which is what produces visibly even results across the treated area.
Both depth control and impedance monitoring are technical features that practitioners care about because they directly affect what the patient sees in the mirror three months after the course of treatment.
What this means for the clinic
A device that handles laxity, vascular conditions, pigmentary conditions, and inflammatory conditions on every Fitzpatrick skin type is a different commercial proposition to a device that handles laxity well on lighter skin types only. The patient mix that walks through a typical UK aesthetic clinic is broader than the laxity only audience that most RF microneedling devices were designed for. The clinic that can say yes to the rosacea patient, yes to the melasma patient, yes to the Fitzpatrick V patient with acne scarring, captures revenue that other clinics in the same area are referring out or refusing.
This is the commercial argument behind the clinical argument. Dual wave is not a feature for its own sake. It is a clinical capability that translates directly into a wider treatable patient base, which translates into more bookings, higher utilisation, and better return on the device investment.
Next steps
The clinical detail above is a starting point. The honest way to assess Sylfirm X is to see the device demonstrated, ideally on a clinical case that matches the patient profile your clinic struggles to treat with current equipment. Live demonstrations are available at your clinic or online, and we will walk through Pulsed Wave and Continuous Wave protocols, depth selection, and impedance monitoring in real time.
Get in touch to book a live demonstration and discuss whether Sylfirm X fits your clinical and commercial requirements.
Sylfirm X is distributed in the UK by Novus Medical.